4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Market cap: $45.6M (2/09/2026)
Price: $6.22
Reports Third Quarter 2025 Financial Results
Kezar Life Sciences Implements Workforce Reduction of 70%
Kezar Life Sciences Repays $6.3 Million Under Loan Agreement
Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives
Reports Second Quarter 2025 Financial Results and Provides Business Update
Shareholder votes
Earnings Release
Annual Report to Security Holders
Q3
Q2
Q1
FY 2024
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Amended Registration of Securities
Registration of Securities
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
Automatic Shelf Registration Statement